Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PNT001 in healthy volunteers
NCT04096287Phase 1Completed
- Sponsor
- Pinteon Therapeutics
- Start
- Sep 2019
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) and traumatic brain injury (TBI) comparing PNT001 with Placebo (2 arms). Primary endpoints: Incidence of Treatment Emergent Adverse Events at 16 weeks, Incidence of Treatment Emergent Clinical Laboratory Test Abnormalities at 16 weeks and 5 more. Started Sep 2019; status: completed.
02
Drugs
PNT001
03
Conditions
Alzheimer's disease (AD)traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT04096287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096287.